Significant publications in diabetes pharmacotherapy and technology in 2020

References

• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229.
   PubMed Web of Science ®Google Scholar
• Buonafine M, Bonnard B, Jaisser F. Mineralocorticoid receptor and cardiovascular disease. Am J Hypertens. 2018;31(11):1165–1174.
   PubMed Web of Science ®Google Scholar
• Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 2019;96(2):302–319.
   PubMed Web of Science ®Google Scholar
• Jaisser F, Farman N, Touyz RM. Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol Rev. 2016;68(1):49–75.
   PubMed Web of Science ®Google Scholar
• Liu LCY, Schutte E, Gansevoort RT, et al. Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs. 2015;24(8):1123–1135.
   PubMed Web of Science ®Google Scholar
• Katayama S, Yamada D, Nakayama M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications. 2017;31(4):758–765.
   PubMed Web of Science ®Google Scholar
• Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105–2114.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–894.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263.
   PubMed Web of Science ®Google Scholar
• Feig DS, Donovan LE, Zinman B, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020;8(10):834–844.
   PubMed Web of Science ®Google Scholar
• Feig DS, Hwee J, Shah BR, et al. Trends in incidence of diabetes in pregnancy and serious perinatal outcomes: a large, population-based study in Ontario, Canada, 1996–2010. Diabetes Care. 2014;37(6):1590–1596.
   PubMed Web of Science ®Google Scholar
• Murphy HR, Bell R, Cartwright C, et al. Improved pregnancy outcomes in women with type 1 and 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study. Diabetologia. 2017;60(9):1668–1677.
   PubMed Web of Science ®Google Scholar
• Langer O, Anyaegbunam A, Brustman L, et al. Pregestational diabetes: insulin requirements throughout pregnancy. Am J Obstet Gynecol. 1988;159(3):616–621.
   PubMed Web of Science ®Google Scholar
• Vanky E, Zahlsen K, Spigset O, et al. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril. 2005;83(5):1575–1578.
   PubMed Web of Science ®Google Scholar
• Ibrahim MI, Hamdy A, Shafik A, et al. The role of adding metformin in insulin resistant diabetic pregnant women: a randomized controlled trial. Arch Gynecol Obstet. 2014;289(5):959–965.
   PubMed Web of Science ®Google Scholar
• Ainuddin JA, Karim N, Zaheer S, et al. Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group randomized, open label study in patients with type 2 diabetes in pregnancy. J Diabetes Res. 2015;2015:325851.
   PubMed Web of Science ®Google Scholar
• Beyuo T, Obed SA, Adjepong-Yamoah KK, et al. Metformin versus insulin in the management of pre-gestational diabetes mellitus in pregnancy and gestational diabetes at the Korle Bu Teaching Hospital: a randomized clinical trial. PLoS One. 2015;10(5):e0125712.
   PubMed Web of Science ®Google Scholar
• Hickman MA, McBride R, Boggess KA, et al. Metformin compared with insulin in the treatment of pregnant women with overt diabetes: a randomized controlled trial. Am J Perinatol. 2013;30(6):483–490.
   PubMed Web of Science ®Google Scholar
• Waheed S, Malik FP, Mazhar SB. Efficacy of metformin versus insulin in the management of pregnancy with diabetes. J Coll Physicians Surg Pak. 2013;23(12):866–869.
   PubMed Web of Science ®Google Scholar
• Cesta CE, Cohen JM, Pazzagli L, et al. Antidiabetic medication use during pregnancy: an international utilization study. BMJ Open Diab Res Care. 2019;7(1):e000759.
   PubMedGoogle Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Klaff L, Cao D, Dellva MA, et al. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study. Diabetes Obes Metab. 2020;22(10):1799–1807.
   PubMedGoogle Scholar
• Russell-Jones D, Bode BW, De Block C, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care. 2017;40(7):943–950.
   PubMedGoogle Scholar
• Heise T, Linnebjerg H, Coutant D, et al. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: a phase 1 randomized, crossover study. Diabetes Obes Metab. 2020;22(10):1789–1798.
   PubMedGoogle Scholar
• Blevins T, Zhang Q, Frias JP, et al. Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care. 2020;43(12):2991–2998.
   PubMedGoogle Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Bajaj HS, Janež A, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020;383(22):2107–2116.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Del Prato S. Basal weekly insulins: the way of the future! Metabolism. 2022;126:154924.
   PubMedGoogle Scholar
• Takase T, Nakamura A, Yamamoto C, et al. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial. J Diabetes Investig. 2019;10(3):699–705.
   PubMedGoogle Scholar
• Billings LK, Handelsman Y, Heile M, et al. Health-related quality of life assessments with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus. J Manag Care Spec Pharm. 2018;24(9–aSuppl):S30–S41.
   PubMedGoogle Scholar
• Breton MD, Kanapka LG, Beck RW, et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med. 2020;383(9):836–845.
   PubMedGoogle Scholar
• Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1707–1717.
   PubMed Web of Science ®Google Scholar
• Castorino K, Polsky S, O’Malley G, et al. Performance of the Dexcom G6 continuous glucose monitoring system in pregnant women with diabetes. Diabetes Technol Ther. 2020;22(12):943–947.
   PubMedGoogle Scholar
• Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicenter international randomized controlled trial. Lancet. 2017;390(10110):2347–2359.
   PubMed Web of Science ®Google Scholar
• Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–1603.
   PubMed Web of Science ®Google Scholar
• Dexcom CGM. Where can I insert my G6 sensor? Updated March 25, 2021. [Cited 2021 Dec 8]. https://www.dexcom.com/faqs/where-can-i-insert-my-dexcom-g6-sensor
   Google Scholar
• Shah VN, Laffel LM, Wadwa RP, et al. Performance of a factory-calibrated real-time continuous glucose monitoring system utilizing an automated sensor applicator. Diabetes Technol Ther. 2018;20(6):428–433.
   PubMed Web of Science ®Google Scholar
• Grunberger G, Bhargava A, Ly T, et al. Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: the VIVID study. Diabetes Obes Metab. 2020;22(3):434–441.
   PubMedGoogle Scholar
• Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28(5):1240–1244.
   PubMedGoogle Scholar
• Andres J, Clements JN. A practical guide to concentrated insulin for pharmacists. J Pharm Pract. 2014;27(5):481–486.
   PubMedGoogle Scholar
• Segal AR, Brunner JE, Burch FT, et al. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm. 2010;67(18):1526–1535.
   PubMed Web of Science ®Google Scholar
• Reutrakul S, Wroblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol. 2012;6(2):412–420.
   PubMedGoogle Scholar
• Cochran EK, Valentine V, Samaan KH, et al. Practice tips and tools for the successful use of U-500 regular human insulin: the diabetes educator is key. Diabetes Educ. 2014;40(2):153–165.
   PubMedGoogle Scholar
• Ballani P, Tran MT, Navar MD, et al. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care. 2006;29(11):2504–2505.
   PubMedGoogle Scholar
• Quinn SL, Lansang MC, Mina D. Safety and effectiveness of U-500 insulin therapy in patients with insulin-resistant type 2 diabetes mellitus. Pharmacotherapy. 2011;31(7):695–702.
   PubMedGoogle Scholar
• Hood RC, Arakaki RF, Wysham C, et al. Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: a randomized, titration-to-target clinical trial. Endocr Pract. 2015;21(7):782–793.
   PubMed Web of Science ®Google Scholar
• Kabul S, Hood RC, Duan R, et al. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial. Health Qual Life Outcomes. 2016;14(1):139.
   PubMedGoogle Scholar
• Pratley RE, Kanapka LG, Rickels MR, et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial. JAMA. 2020;323(23):2397–2406.
   PubMedGoogle Scholar
• American Diabetes Association. 13. Older adults: standards of medical care in diabetes—2022. Diabetes Care. 2022;45(Suppl.1):S195–S207.
   PubMedGoogle Scholar
• Battelino T, Phillip M, Bratina N, et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34(4):795–800.
   PubMed Web of Science ®Google Scholar
• Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317:371.
   PubMed Web of Science ®Google Scholar
• Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–1640.
   PubMed Web of Science ®Google Scholar